Roivant Sciences LTD 8-K filings
NASDAQ
Roivant Sciences Ltd. announced positive Phase 2 trial results for brepocitinib in non-infectious uveitis and a $1.5 billion share repurchase program, including the repurchase of all shares held by Sumitomo Pharma.
NASDAQ
8-K: Roivant Reports $5.1 Billion Net Income Following Telavant Sale, Provides Clinical Pipeline Update
Roivant Sciences reported a significant net income of $5.1 billion for the quarter ending December 31, 2023, driven by the sale of Telavant to Roche, and provided updates on its clinical programs.